By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Celyad (Formally Known as Cardio3 BioSciences) 

Parc de L’Alliance
9, Boulevard de France
Braine - L’Alleud    1420  Belgium
Phone: 32-2-790-35-30 Fax: 32-2-790-35-35



Company News
Celyad Successfully Completes Safety Follow-Up Of The First Patient At The Fourth Dose Level In The NKR-2 Phase I Trial 7/14/2016 9:39:45 AM
Celyad Hammers Out NKR-2 T-cell Immunotherapy Deal Worth $311.5 Million with Ono Pharma 7/11/2016 6:06:18 AM
Celyad To Host An Immuno-Oncology R&D Analyst Day On March 24th In New York City 2/29/2016 7:56:22 AM
Invetech And Celyad Announce Collaboration To Realize The Commercial cGMP Production Of C-Cure 2/3/2016 6:02:20 AM
Celyad Announces The Publication Of Its CHART-1 Trial Design Methods Paper In The European Journal Of Heart Failure 12/16/2015 8:07:32 AM
Celyad Treats First Patient Of Second Cohort In NKG2D CAR T-Cell Phase I Trial 12/1/2015 7:21:08 AM
Celyad Announces Third Quarter 2015 Business Update 11/19/2015 8:10:51 AM
Celyad Successfully Completes 30-Day Safety Follow-Up Of First Patient Cohort In NKG2D CAR T-Cell Phase I Trial 11/10/2015 7:38:47 AM
First US Patent Covering Allogeneic Chimeric Antigen Receptor T Cells ("CAR-T") Modified To Reduce Immunogenicity Is Awarded To Celyad 10/23/2015 8:06:05 AM
Celyad Announces the Appointment Of Dr. Frederic Lehmann As Vice President Immuno-Oncology 9/15/2015 6:39:44 AM